A Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

Trial Profile

A Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2013

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Diabetic nephropathies
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Oct 2012 Status changed from active, no longer recruiting to discontinued, as reported in a Reata Pharmaceuticals media release.
    • 18 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 May 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top